• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis
【24h】

Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis

机译：日本透析学会治疗慢性血液透析患者心血管疾病的指南

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The annual all-cause mortality in chronic dialysis patients in our country is within 10%, indicating that the outcome of dialysis therapy in Japan is one of the best in the world. It is nothing short of extraordinary to maintain favorable survival like this despite challenging conditions such as aging of the patients and increase in the proportion of patients on long-term dialysis and with diabetes mellitus. We can be proud of our achievement. Novel therapeutic strategics for dialysis patients have been developed, such as anti-hypertensive drugs (e.g. angiotensin II receptor blockers, calcium channel blockers and beta blockers), treatment of anemia (e.g. crythropoiesis stimulating agents), and management of chronic kidney disease-mineral and bone disorder (CKD-MBD) (e.g. activated vitamin D, calcimimctics, and new phosphate binders).
机译：我国慢性透析患者的年全因死亡率在10％以内，这表明日本的透析治疗结果是世界上最好的之一。尽管存在挑战性的条件，例如患者的衰老以及长期透析和糖尿病患者的比例增加，但保持如此良好的存活率仍是非同寻常的。我们可以为我们的成就感到自豪。已经开发出针对透析患者的新型治疗策略，例如抗高血压药（例如血管紧张素II受体阻滞剂，钙通道阻滞剂和β受体阻滞剂），贫血的治疗（例如促红细胞生成剂）以及慢性肾脏疾病的治疗（矿物质和糖尿病）骨骼疾病（CKD-MBD）（例如活化的维生素D，钙化钙和新的磷酸盐结合剂）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号